MP07-06 VERY-SMALL-NUCLEAR CIRCULATING TUMOR CELL (VSNCTC) AS A PUTATIVE BIOMARKER FOR VISCERAL METASTASIS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

Abstract

You have accessJournal of UrologyProstate Cancer: Markers II1 Apr 2016MP07-06 VERY-SMALL-NUCLEAR CIRCULATING TUMOR CELL (VSNCTC) AS A PUTATIVE BIOMARKER FOR VISCERAL METASTASIS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) Jie-Fu Chen, Hao Ho, Elisabeth Hodara, Alexandar Ureno, Ann Go, Elizabeth Kaufman, Margarit Sievert, Daniel Luthringer, Jiaoti Huang, Ker-Chau Li, Zunfu Ke, Leland Chung, Hsian-Rong Tseng, and Edwin Posadas Jie-Fu ChenJie-Fu Chen More articles by this author , Hao HoHao Ho More articles by this author , Elisabeth HodaraElisabeth Hodara More articles by this author , Alexandar UrenoAlexandar Ureno More articles by this author , Ann GoAnn Go More articles by this author , Elizabeth KaufmanElizabeth Kaufman More articles by this author , Margarit SievertMargarit Sievert More articles by this author , Daniel LuthringerDaniel Luthringer More articles by this author , Jiaoti HuangJiaoti Huang More articles by this author , Ker-Chau LiKer-Chau Li More articles by this author , Zunfu KeZunfu Ke More articles by this author , Leland ChungLeland Chung More articles by this author , Hsian-Rong TsengHsian-Rong Tseng More articles by this author , and Edwin PosadasEdwin Posadas More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.2209AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Patients with metastatic castration-resistant prostate cancer (mCRPC) who develop visceral metastasis (VM) have poorer clinical outcomes in comparison to those without VM. Currently, VM are discovered late in the disease course clinical course of mCRPC-VM and this aggressive natural history typically culminates in organ failure. There are no existing tests that identify men at risk for VM other than radiography. Our team performed circulating tumor cell (CTC) enumeration using NanoVelcro CTC Assay (CytoLumina, Los Angeles, CA) on prostate cancer patients across the spectrum of metastatic states: no metastasis, non-visceral metastasis, and VM. We identified an association between the presence of very-small-nuclear CTCs (vsnCTCs, DAPI+/Cytokeratin+/CD45- with nuclear size < 8.5μm) and VM. Serial enumeration studies suggested the emergence of vsnCTCs occurred before the detection of VM (Chen JF et al. Cancer. 2015). We then hypothesized that presence of vsnCTC signals the presence of VM and has predictive and prognostic value with respect to VM. METHODS We identified mCRPC patients who had progressed through next generation hormonal maneuvers such as abiraterone, enzalutamide, or an equivalent drug. Serial blood specimens were used for vsnCTC enumeration using NanoVelcro CTC Assay as previously published. The vsnCTC counts were related to the presence and development of VM (evaluated by radiography) as well as the response to anti-cancer treatment. RESULTS Blood specimens were identified from 28 patients who met the eligibility criteria; 16/28 patients presented with VM and 12/28 had bone-only disease at their first CTC enumeration. Five out of 12 non-VM patients developed VM during follow-up, and vsnCTCs were detected 86-196 days prior to radiographic detection of VM (true positive); 3/12 had vsnCTCs detected but no VM was found by the time of analysis (false positive). None of the vsnCTC(-) patients developed VM. vsnCTCs were detected in 21/21 VM patients compared to 3/12 non-VM patients. Reduction of vsnCTC count occurred at initiation of anti-cancer treatment; transition from vsnCTC(-) to vsnCTC(+) was seen prior to progression under the treatment. CONCLUSIONS vsnCTC is associated with the presence of VM and is a potential biomarker for predicting the development of VM and monitoring the treatment response in mCRPC. Transition from vsnCTC(-) to vsnCTC(+) was associated with the development of VM and progression under the treatment. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e78 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Jie-Fu Chen More articles by this author Hao Ho More articles by this author Elisabeth Hodara More articles by this author Alexandar Ureno More articles by this author Ann Go More articles by this author Elizabeth Kaufman More articles by this author Margarit Sievert More articles by this author Daniel Luthringer More articles by this author Jiaoti Huang More articles by this author Ker-Chau Li More articles by this author Zunfu Ke More articles by this author Leland Chung More articles by this author Hsian-Rong Tseng More articles by this author Edwin Posadas More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...